Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. Design Quantitative benefit-harm and economic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pink, Joshua, Lane, Steven, Pirmohamed, Munir, Hughes, Dyfrig A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204867/
https://www.ncbi.nlm.nih.gov/pubmed/22042753
http://dx.doi.org/10.1136/bmj.d6333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204867/
https://www.ncbi.nlm.nih.gov/pubmed/22042753
http://dx.doi.org/10.1136/bmj.d6333

Ejemplares similares